Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Amyloidosis
Status
OpenFund Type
Copay/PremiumMaximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
500% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Acetadote
- Acetylcysteine Novaplus
- Adoxa
- Alkeran
- Amvuttra
- Avidoxy
- Bortezomib
- Cetylev
- Cyclophosphamide
- Darzalex
- Darzalex Faspro
- Decadron
- Dexamethasone
- Dexpak Taperpak
- Dextenza
- Dexycu
- Doxycycline
- Dxevo
- Evomela
- Gnc Nac 600
- Hidex
- Inotersen
- Ixazomib
- Lenalidomide
- Mason Natural Nac
- Maxidex
- Melphalan
- Monodox
- N-acetylcysteine
- Ninlaro
- Okebo
- Onpattro
- Oracea
- Ozurdex
- Patisiran
- Pomalidomide
- Pomalyst
- Rayos
- Revlimid
- Tafamidis
- Taperdex
- Targadox
- Tegsedi
- Velcade
- Vibramycin Monohydrate
- Vyndamax
- Vyndaqel
- Wainua
Fund Definition
Co-payment or premium assistance for eligible beneficiaries to obtain prescription drug (or biologics) for the treatment of Amyloidosis.
Grant Utilization
HealthWell estimates that patients use an average of $5,505 during their 12-month grant period for this disease area.
Consider Premium Assistance
Under this fund, HealthWell can assist with premium costs. Medicare supplemental policies can help with cost shares related to many aspects of your health care. Using a HealthWell grant to cover premiums may be a better option than treatment-specific cost shares.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
To qualify for assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Amyloidosis
Amyloidosis represents several different disease types where an abnormal protein called amyloid is produced. Amyloid protein fibers can attach and deposit into organs, tissues, nerves and other places in the body, affecting normal function of the area. As the protein increases, health problems and organ damage may occur, according to the Amyloidosis Foundation. Amyloidosis sometimes develops when a person has certain forms of cancer, such as multiple myeloma, Hodgkin’s disease or familial Mediterranean fever (an intestinal disorder). Systemic amyloidosis is slowly progressive and fatal if untreated.
Source: Amyloidosis Foundation